Table 1.

Long-term studies on hydroxyurea use in children with sickle cell disease

Reference 6 Reference7 Reference 8 
No. patients at inclusion 84 101 93  
Mean age at inclusion (y) 9.8 ± 3.2 9.8 ± 0.4 7  
No. patients after 2 y 35 45 61  
No. patients after 3 y ND 36 44 
Malignancy 1, not related to HU 
Reference 6 Reference7 Reference 8 
No. patients at inclusion 84 101 93  
Mean age at inclusion (y) 9.8 ± 3.2 9.8 ± 0.4 7  
No. patients after 2 y 35 45 61  
No. patients after 3 y ND 36 44 
Malignancy 1, not related to HU 

ND indicates not determined.